Wedbush Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $37

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $44 to $37.